3 0 n o v e m b e r 2 0 1 7 | v o L 5 5 1 | n A T U r e | 6 5 3 LeTTer Eukaryotic transcription-coupled repair (TCR) is an important and well-conserved sub-pathway of nucleotide excision repair that preferentially removes DNA lesions from the template strand that block translocation of RNA polymerase II (Pol II) 1,2 . Cockayne syndrome group B (CSB, also known as ERCC6) protein in humans (or its yeast orthologues, Rad26 in Saccharomyces cerevisiae and Rhp26 in Schizosaccharomyces pombe) is among the first proteins to be recruited to the lesion-arrested Pol II during the initiation of eukaryotic TCR 1,3-10 . Mutations in CSB are associated with the autosomal-recessive neurological disorder Cockayne syndrome, which is characterized by progeriod features, growth failure and photosensitivity 1 . The molecular mechanism of eukaryotic TCR initiation remains unclear, with several long-standing unanswered questions. How cells distinguish DNA lesion-arrested Pol II from other forms of arrested Pol II, the role of CSB in TCR initiation, and how CSB interacts with the arrested Pol II complex are all unknown. The lack of structures of CSB or the Pol II-CSB complex has hindered our ability to address these questions. Here we report the structure of the S. cerevisiae Pol II-Rad26 complex solved by cryo-electron microscopy. The structure reveals that Rad26 binds to the DNA upstream of Pol II, where it markedly alters its path. Our structural and functional data suggest that the conserved Swi2/Snf2-family core ATPase domain promotes the forward movement of Pol II, and elucidate key roles for Rad26 in both TCR and transcription elongation.
(EC) bound to Rad26 (hereafter referred to as the Pol II-Rad26 complex), as well as a 6.4 Å structure of a Pol II EC from the same sample, and built pseudo-atomic models using Rosetta (see Methods, Fig. 2 and Extended Data Figs 2 and 3 ). The structure of Pol II-Rad26 revealed that Rad26 binds to the DNA upstream of Pol II EC (Figs 2c, e and 3a, c) and sits between the Pol II clamp (Rpb2 side) and stalk (Rpb4/7) regions 18 , in agreement with our DNase I foot-printing assay (Fig. 3d ). Most Pol II subunits adopt similar conformations in both complexes, with some local changes at the interfaces between Pol II and Rad26 (Extended Data Fig. 3b-d) .
We observed several unique structural features in the Pol II-Rad26 complex. Most notable is the approximately 80° bending of the upstream DNA duplex region in the presence of Rad26 (Fig. 3b ), which has not been reported for any structure involving Pol II 18, 19 . To establish that the bending is a consequence of Rad26 binding and not of lesion-induced bending subsequently stabilized by Rad26, we solved the structure of a Pol II EC with a CPD lesion in the downstream DNA (see Methods) (Extended Data Fig. 4 ). In this structure, lacking Rad26, the upstream DNA is not visible in the cryo-EM map, as was the case for the Pol II EC with undamaged scaffold, indicating that Rad26 is responsible for bending the upstream DNA. The Pol II-Rad26 map showed continuous density for a full transcription bubble ( Fig. 3a) , in contrast to Pol II EC, in which a considerable portion of the nontemplate strand is disordered (Figs 2c, d and 3b ), as previously reported for other Pol II EC structures 19, 20 . This suggests that the binding of Rad26 to Pol II EC may restrain the flexibility of the bubble. The alteration of the potential interaction landscape of Pol II by Rad26 may facilitate the recruitment of downstream repair factors that assemble at the DNA lesion site 1 .
The two RecA-like lobes of Rad26, which fit well into the density (Fig. 2c , e and Extended Data Fig. 3g, h) , bind the upstream DNA duplex region and upstream fork of the transcription bubble ( Fig. 3c ) and adopt essentially an active closed conformation (Figs 2e and 3c ) similar to that of Rad54 and the recently published Snf2-nucleosome complex 21, 22 . We did not detect density for the N-and C-terminal regions of Rad26 or the Rad26-specific loop insertions (Extended Data Fig. 1 ), indicating that these regions are either disordered or adopt multiple conformations and were averaged out during reconstruction.
Another unique feature of our structure is the insertion of a Rad26 HD2-1 'wedge' between the DNA strands at the fork of an extended upstream transcription bubble ( Fig. 3c, e ). This region is highly conserved among CSB family members, but not in other members of the Swi2/Snf2 superfamily (Extended Data Fig. 5 ). The affinity of Rad26 for Pol II EC increases when the upstream fork of the transcription bubble is AT-rich (Extended Data Fig. 6a-d ), suggesting that weaker base pairing facilitates the interaction of Rad26 with
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Pol II EC and bubble opening. A prediction from these data would be that extending the upstream fork of the transcription bubble should increase the affinity of Rad26 for Pol II EC. Indeed, mismatch-driven upstream bubble opening significantly increased the binding of Rad26 to Pol II EC ( Fig. 3f ).
Rad26 also binds directly to Pol II ( Fig. 3g ), consistent with its residual binding affinity for a Pol II EC containing a mini-scaffold with no protruding double-stranded DNA (Extended Data Fig. 6e -h). The major interaction interface between Rad26 and Pol II involves lobe 2 of Rad26 and the Rpb2 subunit in Pol II ( Fig. 3g ). We also observed density in our cryo-EM map extending between lobe 1 of Rad26 and both the coiled-coil domain in Rpb1 and the Rpb4/7 stalk. Although we could not build a full model within those densities owing to their lower resolution, these Pol II regions are common docking sites for several transcription factors, including the initiation factor TFIIE and the elongation factor Spt4-Spt5 18, 23 
Rad26 and the upstream DNA 23 (Extended Data Fig. 7 ). This suggests an important functional interplay between Rad26 and other transcription factors during transcription and TCR through direct competition for binding to Pol II. This explains the early observation that Rad26 antagonizes the repression of TCR by Spt5 and Spt4 24, 25 . Similarly, the overlap between the binding sites of Rad26 and TFIIE accounts for the observation that Rad26 (CSB) is only required for efficient TCR during elongation 1 , but not initiation, when its binding site would be occupied by TFIIE.
Rad26 belongs to the Swi2/Snf2 family of ATP-dependent 3′ -to-5′ single-stranded DNA translocases. To understand which DNA strand Rad26 tracks in the Pol II-Rad26 complex, we superimposed the structure of the yeast Snf2 protein from a recent cryo-EM structure of the Snf2-nucleosome complex (Protein Data Bank (PDB) accession 5X0Y) 22 on the Rad26 ATPase domain in our structure (Fig. 4a, b and Extended Data Fig. 8 ). Although our alignment was driven exclusively by the protein moieties, both the proteins and the regions of DNA to which they bind superimpose well ( Fig. 4b and Extended Data Fig. 8 ). Snf2 tracks a single strand of the nucleosomal DNA in a 3′ -to-5′ direction ( Fig. 4b ). Given its fixed position relative to the histone octamer, Snf2 effectively 'pulls' on the DNA. Analogously, Rad26 would pull the template strand away from Pol II ( Fig. 4c ), promoting Pol II forward translocation and resulting in its bypassing certain translocation barriers ( Fig. 1c, d) 16, 26 . The direction of Rad26 translocation is also consistent with the reported strand annealing activity for CSB 27 .
We tested this model directly by probing whether Rad26 could resolve Pol II backtracking in an ATP-dependent manner ( Fig. 5a, b ). We used TFIIS-stimulated RNA cleavage by Pol II to detect the presence of backtracking induced with a combination of a pausing sequence and nucleotide removal. We observed a significant reduction in RNA cleavage products only in the presence of wild-type Rad26 and dATP ( Fig. 5c, d ). Together, our data suggest that Rad26 can promote the forward motion of Pol II in an ATP-dependent manner.
Several observations from our structure support the conservation of the Pol II-Rad26 (or Pol II-CSB) complex from yeast to humans. Given the conservation in the core ATPase domain of Rad26 (Extended Data Fig. 1 ) 3,4 , we expect the structure of the CSB core domain to be very similar. The structural conservation between mammalian and yeast Pol II EC has been established 28 . Finally, most of the Rad26-DNA and Rad26-Pol II interaction interfaces we identified are highly conserved between yeast and humans.
Although the differences between prokaryotic and eukaryotic TCR are well documented 1 , our Pol II-Rad26 structure revealed some general similarities between them. First, Rad26 and the prokaryotic transcription-repair coupling factor Mfd bind upstream of RNA polymerase and facilitate its forward translocation to rescue transcriptional Letter reSeArCH arrest. Second, both Rad26 and Mfd interact with the structurally conserved second-largest subunit of the polymerase (Rpb2 for Pol II and beta subunit for RNAP), and essentially the same side of RNA polymerase 29 . Our data suggest a unified mechanistic model for the role of Rad26 in both TCR and transcription ( Fig. 5e ). Rad26 recognizes a stalled Pol II and can reduce its dwell time by preventing backtracking, promoting Pol II forward translocation on non-damaged templates, and increasing the chances of transcriptional bypass through less bulky DNA lesions 16, 26 , all of which stimulate transcription elongation 16 (Fig. 5e ). However, Rad26 fails to promote efficient transcriptional bypass of bulky DNA lesions that lead to strong blockage of translocation (such as CPD lesions) 17 (Fig. 1e) . A comparison of our Pol II-Rad26 structure and a CPD-arrested Pol II EC showed a notable structural similarity in the core 10-subunit Pol II region and the active sites ( Fig. 4d-f ), suggesting that a CPD lesion would probably have no effect on the interactions between Pol II and Rad26. In agreement with this, the binding affinities between Rad26 and a Pol II EC carrying either a non-damaged or a CPD lesion-containing scaffold are indistinguishable (Extended Data Fig. 6i, j) . These observations suggest that only the interaction between Rad26 and a Pol II persistently arrested at a bulky lesion would lead to the initiation of TCR (Fig. 5e ).
The structure of the Pol II-Rad26 complex also provides insights into the roles of CSB in DNA lesion recognition and verification in eukaryotic TCR initiation. TCR and global genome nucleotide excision repair (GG-NER) have been suggested to have similar tripartite lesion recognition and verification steps, with the first DNA lesion recognition step in TCR being mediated by blockage of Pol II transcription instead of XPC 30 (Extended Data Fig. 9 ). However, the role of CSB in this lesion recognition step is not clear. We propose that CSB (Rad26) has a central role in the first DNA lesion recognition step ( Fig. 5e ) and presents new protein interaction interfaces that could facilitate loading downstream repair factors 1 , such as UVSSA, CSA, XPG and TFIIH in humans (Extended Data Fig. 9 ). TFIIH would use its XPB and XPD helicases to induce backtracking in Pol II and verify the presence of a DNA lesion on the template strand (step 2). The final step, XPAdependent lesion verification, is expected to be the same for both GG-NER and TCR (step 3) 30 (Extended Data Fig. 9 ). A full understanding of the mechanistic details of this model awaits further investigation.

MethOdS
Protein expression and purification. The coding sequence of S. cerevisiae Rad26 was cloned from Saccharomyces genomic DNA into a pGEX6p-1 based vector (GE Healthcare). An N-terminal hexa-histidine tag and Escherichia coli trigger factor protein were added to the construct to facilitate protein expression and purification. A precision protease recognition sequence was inserted between the trigger factor and Rad26. Rad26 mutations were generated by PCR using the full-length Rad26 sequence as template. All Rad26 constructs were confirmed by DNA sequencing.
Recombinant Rad26 proteins were expressed in E.coli strain Rosetta 2(DE3) (Novagen). Cells were transformed and grown in LB at 37 °C to an OD 600 nm of 0.6, and expression was induced by 0.1 mM IPTG for 16 h at 20 °C. The cells were lysed in buffer A (20 mM Tris-HCl (pH 7.5), 500 mM NaCl, 5% glycerol, 1 mM 2-mercaptoethanol). After centrifugation, the supernatant lysate was applied to a HisTrap HP column (GE Healthcare) equilibrated in buffer B (buffer A plus 10 mM imidazole). The column was washed with 20 column volumes of buffer B and eluted with buffer A containing 200 mM imidazole. The eluate was then applied to a Hi-Trap Heparin column (GE Healthcare), equilibrated in buffer C (20 mM Tris-HCl (pH 7.5), 400 mM NaCl, 5% glycerol, 1 mM 2-mercaptoethanol) and eluted in buffer A with a linear gradient of 400-1,000 mM NaCl. The eluate was then applied to a Hi-Trap SP HP column (GE Healthcare), equilibrated in buffer D (20 mM Tris-HCl (pH 7.5), 250 mM NaCl, 5% glycerol, 1 mM 2-mercaptoethanol) and eluted in buffer A with a linear gradient of 250-1,000 mM NaCl. To improve the purity further, Rad26-containing fractions from the Hi-Trap SP HP column were applied to a Superdex 200 10/300 GL size exclusion column (GE Healthcare), equilibrated in buffer E (20 mM Tris-HCl (pH 7.5), 500 mM NaCl, 5% glycerol, 1 mM DTT). The Rad26-containing fractions were pooled, concentrated to 2 mg ml −1 and stored at − 80 °C.
S. cerevisiae 12-subunit Pol II was purified essentially as previously described 31, 32 . In brief, Pol II (with a recombinant protein A tag in the Rpb3 subunit) was purified by affinity chromatography using an IgG column (GE Healthcare), followed by further purification using Hi-Trap Heparin and Mono Q anion exchange chromatography columns (GE Healthcare). In vitro transcription assay. Pol II elongation complexes were assembled essentially as previously described 14, 33 . Radioactively-labelled 10-mer RNA was annealed to the template strand DNA by heating at 95 °C for 2 min followed by slow cooling to room temperature (23 °C). 10 pmol of Pol II was incubated with 4 pmol of RNA-DNA hybrid for 10 min at room temperature (23 °C), and then 2 min at 37 °C. To this, 10 pmol of biotin-labelled non-template strand DNA was added and incubated for 5 min at 37 °C followed by 20 min at room temperature (23°C). The assembled elongation complex was incubated with 20 μ l of Streptavidin magnetic beads (NEB) for 30 min at room temperature (23 °C) and subsequently washed with elongation buffer (EB) (20 mM Tris-HCl (pH 7.5), 5 mM MgCl 2 , 40 mM KCl, 5 mM DTT), followed by EB with 0.3 M NaCl, EB with 1 M NaCl, EB with 0.3 M NaCl and finally EB. The efficiency of elongation complex assembly and bead association was estimated to be 20-50% based on the radioactivity of bead-associated RNA. For transcription assays with Py-Im polyamide roadblock, 0.8 μ M of Py-Im polyamides was incubated with the bead-associated elongation complexes in EB for 3 h at room temperature. The beads were re-suspended in EB and used for transcription assays.
All in vitro transcription was initiated by adding rNTPs mixture to a final concentration of 1 mM each. Additional 3 mM dATP was also included to support Rad26 ATPase activity. After 5 min, Rad26 or TFIIS (final concentration of 100 nM) was added to the reaction mix and kept at 30 °C. For transcription assay from CPD-lesion containing template, Rad26 or TFIIS were added at same time with NTP mixture to visualize the early pausing sites (0.3-3 min). After adding Rad26 or TFIIS, reactions were allowed to continue for the desired time and then quenched (after 1 3, 10, 30, or 60 min) by adding an equal volume of quench-loading buffer (90% formamide, 50 mM EDTA, 0.05% xylene cyanol and 0.05% bromophenol blue). Samples were boiled for 10 min at 95 °C in quench-loading buffer, and the product RNA transcripts were analysed by denaturing PAGE (6 M urea). The gel was visualized by phosporimaging and quantified using Image Laboratory software (BioRad).
For the experiments using TFIIS as a probe to investigate whether Rad26 translocation helps resolve induced backtracking in Pol II (Fig. 5 ), 1 mM rNTPs was first added to Pol II elongation complex with an A-tract template to start transcription. After 20 min of transcription extension, the rNTPs were removed by washing the resin three times to generate backtracked Pol II. 200 nM Rad26 and 3 mM dATP were then added to the reaction mix, which was incubated at 30 °C for 5 min. Finally, 100 nM TFIIS was added and the reaction incubated at 30 °C for 1, 2, 5, or 10 min before being quenched by adding an equal volume of quench-loading buffer. Samples were boiled for 10 min at 95 °C in quench-loading buffer, and the product RNA transcripts were analysed by denaturing PAGE (6 M urea). The gel was visualized by phosporimaging and quantified using Image Laboratory software (BioRad). Supplementary Tables 1 and 2 . Electrophoretic mobility shift assay. To examine the formation of Pol II-Rad26 complexes, an aliquot of 20 nM transcription scaffold with radiolabelled RNA was incubated with 50 nM Pol II in the binding buffer (20 mM Tris, pH 7.5, 5 mM MgCl 2 , 5 mM DTT, 40 mM KCl, 50 mM NaCl, 5% glycerol, 0.1 mg ml −1 BSA) at 23 °C for 10 min to form the elongation complex. Rad26 was added at specified concentrations and the reactions were incubated for an additional 30 min at 23 °C. The reactions were then run on a 4.5% native PAGE in TBE buffer (pH 8.0) with 2 mM MgCl 2 for 2.5 h at 4 °C. Labelled Pol II EC and Pol II-Rad26 complexes were visualized by phosporimaging and quantified using Image Laboratory software (BioRad). DNase I footprinting. An aliquot of 20 nM Pol II EC (with 5′ -32 P-labelled template DNA strand) was incubated with 0-150 nM Rad26 in the binding buffer (see above) at 23 °C for 30 min. Then DNase I (NEB) was added to a final concentration of 0.04 U μ l −1 and the digestion was carried out for 1 min (50 s if Rad26 was absent) at 23 °C. The reactions were stopped by addition of 10 μ l quench-loading buffer. DNA products were heat-denatured at 95 °C for 5 min and separated by 7% denaturing PAGE gel. Labelled DNA products were visualized by phosphorimaging and quantified using Image Laboratory software (BioRad). Preparation of the Pol II-Rad26 complex for electron microscopy. PAGEpurified RNA oligonucleotides were purchased from Dharmacon, template and non-template DNA oligonucleotides were obtained from IDT. HPLC-purified CPD lesion-containing template was purchased from TriLink. The RNA, template DNA (non-damaged or CPD lesion containing) and non-template DNA were annealed to form the scaffold as described above. To form the Pol II EC, Pol II and the scaffold were incubated in elongation buffer (20 mM Tris (pH 7.5), 40 mM KCl and 5 mM dithiothreitol (DTT)). To form the Pol II-Rad26 complex, Rad26 was added to Pol II EC and incubated for 30 min at 23 °C. The final buffer composition was 20 mM Tris-HCl (pH 7.5), 5 mM MgCl 2 , 10 mM DTT, 40 mM KCl, 100 mM NaCl and 2% glycerol and the final concentrations of the different components were 330 nM Pol II, 600 nM Rad26, 300 nM template DNA, 330 nM non-template DNA and 360 nM RNA. The same procedure was used to assemble Pol II EC containing a site-specific CPD lesion, except with the following modification. To increase the randomness of Pol II EC (CPD) particle orientations on the EM grid, the Pol II EC (CPD) complex (1.2 μ M) was crosslinked with 1 mM BS3 (Thermo) for 30 min at 23 °C, then quenched with 50 mM ammonium bicarbonate. The excess BS3 was then removed by overnight dialysis. The final concentration of the Pol II EC (CPD) complex was 900 nM.
DNA and RNA oligonucleotides and scaffolds used in this study. See
The sequences used for elongation complex preparation are as follows: template DNA, 5′ -CGCTCTGCTCCTTCTCCCATCCTCTCGATGGCTATG AGATCAACTAG-3′ ; CPD lesion-containing template DNA, 5′ -CGCTCTGCTC CTTCTCCXXTCCTCTCGATGGCTATGAGATCAACTAG-3′ (XX = CPD lesion); non-template DNA, 5′ -CTAGTTGATCTCATATTTCATTCCTACTCAGGAGA AGGAGCAGAGCG-3′ ; RNA, 5′ -AUCGAGAGGA-3′ . Electron microscopy. An aliquot of 4 μ l of the sample was applied to glowdischarged UltraAuFoil R 1.2/1.3 holey gold grids (Quantifoil Micro Tools GmbH) coated with a thin carbon layer for Pol II-Rad26 and Quantifoil 1.2/1.3 holey carbon grids for Pol II EC (CPD). The grids were blotted and plunge-frozen in liquid ethane using a Vitrobot (FEI). Automated data collection was performed using Leginon 34 on a FEI Talos Arctica operated at 200 kV, equipped with a Gatan K2 Summit direct detector (Gatan Inc.). For the Pol II-Rad26 sample, 8,026 movies were recorded in 'super-resolution mode' at a dose rate of 11.2 electrons pixel −1 s −1 with a total exposure time of 6 s sub-divided into 200 ms frames, for a total of 30 frames. The images were recorded at a nominal magnification of 36,000× resulting in an object-level pixel size of 1.2 Å pixel −1 (0.6 Å per super-resolution pixel). The defocus range of the data was − 0.5 μ m to − 5 μ m. The Pol II EC (CPD) sample adopted a strongly preferred orientation on the grid. To increase the number of orientations, two datasets were collected, with and without bis(sulfosuccinimidyl)suberate (BS3, ThermoFisher Scientific) 23, 35, 36 . A total of 3,690 micrographs were recorded using the above-mentioned parameters except that the total exposure was 7.5 s instead of 6 s. Image processing. The movie frames were aligned using a pre-release version of MotionCor2 37 using the dose-weighted frame alignment option. The aligned micrographs were then manually inspected and unsuitable micrographs (having defects like broken carbon, thick ice, and so on) were discarded. CTF estimation was performed on the non-dose-weighted aligned micrographs using CTFFIND3 38 and micrographs having a 0.5 confidence resolution for the CTF fit worse than 8 Å (as determined in Appion) were excluded from further processing. For an initial reconstruction, DoG Picker 39 was used to select particles from the doseweighted micrographs in a template-independent manner. Relion 1.4 40, 41 was used for the initial round of 3D reconstruction. One more round of particle picking was performed using FindEM 42 with 2D averages from the initial processing serving as templates and the particle picks from this final round were used for further processing. CTF estimation and particle picking were performed within the framework of Appion 43 .
All subsequent processing was done using a pre-release version of Relion 2 44 installed on Amazon Web Services (Ami id: ami-9caa71fc) 45 . Two-dimensional classification was performed to identify 'bad' particles. Only those particles that contributed to 'good' 2D class averages were used for further processing. Following 2D classification, an initial 3D classification was performed using a Pol II EC model (PDB accession 1Y77) 46 as reference and only those particles corresponding to classes showing a strong additional density when compared to EC were selected. The 2D and initial 3D classifications were carried out using 4× binned data (4.8 Å pixel −1 ). For the rest of the steps unbinned images (1.2 Å pixel −1 ) were used. The detailed 3D classification and refinement scheme is shown in Extended Data Fig. 2d . The resolutions of the cryo-EM maps were estimated from Fourier shell correlation (FSC) curves calculated using the gold-standard procedure and the resolutions are reported according to the 0.143 cutoff criterion 47, 48 . FSC curves were corrected for the convolution effects of a soft mask applied to the half maps by high-resolution phase randomization 49 . The density maps were corrected for the modulation transfer function (MTF) of the detector and were sharpened with an automatically estimated negative B factor as implemented in the 'post-process' routine of Relion.
In our initial EM map (Extended Data Fig. 2d ; 4.5 Å Pol II-Rad26 complex structure) the density for Rad26 was more fragmented compared to the rest of the complex. To identify a subset of particles with strong density for Rad26, the signal for the rest of the elongation complex was computationally removed and then focused classification was performed using a mask for Rad26 generated from the initial map 50 . For further processing only those classes that showed a clear upstream DNA density and the complete density for the Rad26 ATPase domain were selected. 19,231 particles (4% of the total particles retained after 2D classification and 12% of the particles assigned to Pol II-Rad26 after the initial 3D classification) were used for the final cryo-EM map of Pol II-Rad26 and the map reached an overall resolution of 5.8 Å. Local resolution of the map was estimated using the local-resolution routine in Relion2 and was used to locally filter the maps. A cryo-EM map of a Pol II EC was also reconstructed from the same data set using the in silico sorting scheme outlined in Extended Data Fig. 2d . The Pol II EC was reconstructed from 24,300 particles and the map reached an overall resolution of 6.4 Å.
For the Pol II EC (CPD) datasets, CTFFIND4 51 was used for CTF estimation and 2D averages of the Pol II-Rad26 complex were used as templates for particle picking using FindEM. A total of 936,200 particles were selected from the two datasets and after several rounds of 2D classifications 144,085 particles were retained for further processing. These particles were refined against the Pol II-Rad26 structure using the heterogeneous refinement regime in CryoSparc 52 . 51,119 particles contributed to the final structure. Analysis of the angular distribution of the particles revealed a strong orientation bias (Extended Data Fig. 4e ), preventing further classification or refinement of the structure. Model building. Rosetta 53-55 was used to build atomic models into the cryo-EM maps of Pol II-Rad26 and Pol II EC. Reference models for Rad26 and different subunits of Pol II were selected based on homology detection using hidden Markov model as implemented in HHpred 56 . (Note, the model for yeast Snf2 protein from a recent cryo-EM structure of the Snf2-nucleosome complex (PDB accession 5X0Y) 22 , which we compare with the Rad26 structure in Fig. 4 and Extended Data Fig. 8 , was not included in our model building.) Reference models were aligned to the EM map using UCSF Chimera 60 . Twenty top-scoring homologous models were used as input in RosettaCM, which then rebuilt missing regions guided by density, and refined the resulting structures using the Rosetta force field augmented with fit-to-density energy 54 . The starting model for the transcription scaffold was generated from previous structures of the transcribing yeast (PDB accession 5C4X) 57 and mammalian (PDB accession 5FLM) Pol II 28 , and was refined using PHENIX real space refinement 58 with nucleic acids-specific LibG restrains. Initially, the Pol II-Rad26 map was divided into three regions: Rad26, Pol II core and Rpb4/7 stalk and the atomic models for each of these regions were refined separately. In each case, several output models were generated (2,000 for Rad26 and 320 each for Pol II core and Rpb4/7 stalk). For each region, the conformation with the best Rosetta energy (including fit-to-density energy) was used for subsequent steps. Regions poorly matching the density following RosettaCM were manually deleted from the templates, and rebuilt de novo.
Once a converged solution was arrived at for all three regions (Rad26, Pol II core and Rpb4/7 stalk), a combined atomic model was refined against the complete EM map of Pol II-Rad26. This was carried out using RosettaCM, in which 200 models were generated. A final refinement step was performed against one of the half-maps from the 4.5 Å structure of Pol II -Rad26 (the training half-map) using Rosetta's Relax protocol 53, 55 to optimize the positions and geometry of the amino acid side chains. Model geometry was verified using Molprobity 59 (Extended Data Fig. 3g ). To estimate over-fitting, FSC work (FSC curve between the refined model and training half-map) and FSC free (FSC curve between the refined model and the other half-map, the test half-map) were calculated. All figures and difference maps were generated using UCSF Chimera 60 and the maps were segmented using Seggar 61 as implemented in UCSF Chimera. Data availability. Cryo-EM maps have been deposited in the Electron Microscopy Data Bank (EMDB), with the following accession numbers: higher-resolution (4.5 Å) Pol II-Rad26 (EMD-8736); final map for Pol II-Rad26 (EMD-8735); locally filtered version of EMD-8735 (EMD-7038); Pol II EC (EMD-8737); and Pol II EC (CPD) (EMD-8885). The atomic models have been deposited in the Protein Data Bank (PDB), with the following accession numbers: Pol II-Rad26 complex (5VVR); and Pol II EC complex (5VVS). Corresponding author(s): Andres E Leschziner
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